Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Department Of Justice Investigates Allergan For Off-Label Promotion Of Botox

This article was originally published in The Pink Sheet Daily

Executive Summary

Georgia U.S. Attorney subpoenas marketing and educational materials related to alleged promotion of Botox for headache, an unapproved use.

You may also be interested in...



Inflamed Language: FDA Sends Harsh Warning Letter To Allergan For Acne Drug

Allergan gets slammed for Aczone Gel promotional claims that FDA says are backed by data "not even nominally statistically significant."

Inflamed Language: FDA Sends Harsh Warning Letter To Allergan For Acne Drug

Allergan gets slammed for Aczone Gel promotional claims that FDA says are backed by data "not even nominally statistically significant."

Public Citizen Attacks Allergan Botox Campaign Featuring Olympic Gold Medalists

Aging Olympians claim Botox helps them maintain their “personal best.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel